Buy, hold, sell: Pro Medicus, BHP, Woolworths shares

S&P/ASX 200 Index (ASX: XJO) shares rose 2.77% and delivered total returns, including dividends, of 7% in FY26. 

On the The Bull this week, two experts give us their views on three ASX 200 shares as the new financial year gets underway.

Let’s check them out. 

Pro Medicus Ltd (ASX: PME)

The Pro Medicus share price fell 28.64% in FY26 amid a broader sector rout. 

However, that 12-month statistic hides the dramatic nature of the Pro Medicus share price rebound since February. 

Since its 52-week low of $107.75 on 24 February, Pro Medicus shares have skyrocketed 94%! 

Morgans has a buy rating on this ASX 200 healthcare share.

In a note issued last week, the broker said: 

PME has re-gained positive momentum (MoMo) off its multi-year lows. The move reflects a closing of the value gap flagged in our recent note (1 June), not any change to the underlying business.

With a >50% price move in June and heavy buying across the network in the mid to low $100s, taking some profits on new and overweight positions is hard to argue against, but absolutely view maintaining positions in PME as a core growth holding.

With the near-term upside/downside skew now less favourable, happy to lock in some outsized profits while maintaining a core growth holding.

Morgans increased its 12-month price target on Pro Medicus shares to $230. 

BHP Group Ltd (ASX: BHP)

The BHP share price soared 62% to finish FY26 at $59.40. 

James Bills from Shaw and Partners has a hold rating on the market’s largest ASX 200 mining share. 

Bills said: 

BHP remains a cornerstone of the Australian sharemarket, underpinned by its scale, diversified commodity exposure and strong balance sheet.

While iron ore continues to drive earnings, BHP is increasingly leveraged to future-facing commodities, including copper, where demand is expected to increase significantly due to growth in data centres and electric vehicles.

Despite near term volatility in commodity prices and sensitivity to global growth, the company’s disciplined capital management and strong cash generation support shareholder returns.

Holding remains appropriate given its quality asset base and exposure to long term structural demand trends.

Woolworths Group Ltd (ASX: WOW)

The Woolworths share price rose 28.67% to $40.03 in FY26.

This made Woolworths shares the best performer within the consumer staples sector last year.

The defensive sector had a strong year in FY26 amid resurgent inflation and rising interest rates. 

The S&P/ASX 200 Consumer Staples Index (ASX: XSJ) rose 10.09% and delivered total returns of 13.72%. 

Bills has a sell rating on Woolworths shares. 

The analyst explains: 

Woolworths is facing increasing competitive pressure in the supermarket sector, along with possible margin compression driven by higher operating and supply chain costs.

While the share price has made a notable recovery since October 2025, the outlook is challenging given increasing cost of living pressures among price sensitive shoppers.

With a relatively modest dividend yield and limited short term catalysts, it may be prudent to reduce exposure and redeploy capital into opportunities with stronger growth prospects.

The post Buy, hold, sell: Pro Medicus, BHP, Woolworths shares appeared first on The Motley Fool Australia.

More reading

• Why BHP and these ASX shares could be strong buys this week
• Should you buy BHP shares in FY27? This is what experts think
• What are experts saying about these red hot ASX shares?
• Healthcare shares lead the ASX 200 again as sector rotation gathers pace
• 9 ASX 200 shares with renewed buy ratings for FY27

Motley Fool contributor Bronwyn Allen has positions in BHP Group. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has recommended BHP Group and Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.